ESMO Breast 2021 | ESMO Breast 2021: What to expect?

Paolo Tarantino, MD, Instituto Europeo di Oncologia, Milan, Italy, shares his highlights from the ESMO Breast 2021 Virtual Congress where international experts will be discussing the latest data in breast cancer, including the use of sacituzumab govitecan which has been approved by the Food and Drug Administration (FDA) for use in metastatic triple negative breast cancer. Additionally, Dr Tarantino discusses another newly developed antibody-drug conjugate (ADC), trastuzumab deruxtecan, which will be presented at the ESMO Breast 2021 virtual meeting and has recently demonstrated efficacy in patients with lung cancer. Lung toxicity in response to the use of ADCs will also be discussed at the meeting, including incidence of interstitial lung disease in this patient population. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.